Identifying treatment weaknesses in a specific type of myeloid leukemia.
Deciphering inv3/t(3;3) Myeloid Leukemia Vulnerabilities via Proteogenomics and N-terminal Proteomics
This study is looking at a specific type of myeloid leukemia linked to changes in chromosome 3, and it aims to find new ways to treat patients who don’t have good options right now by comparing cancer cells to healthy blood cells to see what makes the disease more aggressive.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10997848 on NIH RePORTER |
What this research studies
This research aims to uncover the unique vulnerabilities of myeloid leukemias associated with chromosome 3 rearrangements, specifically inv3/t(3;3). By utilizing advanced proteogenomic techniques, the study will compare cancerous cell lines with healthy blood cells to identify specific genes and proteins that contribute to the disease's aggressiveness. The goal is to find new therapeutic targets for patients who currently lack effective treatment options, as existing therapies have proven ineffective for this leukemia subtype.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with inv3/t(3;3) myeloid leukemia who have not responded to standard treatments.
Not a fit: Patients with other types of leukemia or those who have not been diagnosed with inv3/t(3;3) abnormalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that significantly improve survival rates for patients with inv3/t(3;3) myeloid leukemia.
How similar studies have performed: While research on myeloid leukemias is ongoing, this specific approach targeting inv3/t(3;3) vulnerabilities is relatively novel and has not been extensively tested.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Turmon, Alexandra Chloe — University of California Los Angeles
- Study coordinator: Turmon, Alexandra Chloe
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.